VBIV News and Press, VBI Vaccines Inc. From 07/06/23

2023-07-06 08:32:06 ET Allarity Therapeutics ALLR -53% after pricing public offering to $11M ASLAN Pharmaceuticals Limited ( ASLN ) -33% to host webcast on July 6, 2023, to discuss phase 2b topline data from TREK-AD trial evaluating Eblasakimab in atopic dermatitis. ...

2023-07-05 17:35:55 ET VBI Vaccines ( NASDAQ: VBIV ) is down ~3% in after-hours trading Wednesday after it announced an underwritten public offering and a registered direct offering of common shares and warrants. Raymond James is the sole book-runner. VBI ( ...

VBI Vaccines Inc. ( NASDAQ: VBIV ) (“VBI” or the “Company”), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that it has commenced an underwritten public offering and a registered dire...

Brii Biosciences has acquired worldwide exclusive license to VBI-2601 and an exclusive license for PreHevbri® in the Asia Pacific region VBI will receive gross proceeds of $15 million in upfront payments, subject to near-term milestone achievements, including an equity investment of appr...

2023-07-03 10:30:53 ET Gainers: Ensysce Biosciences ( ENSC ) +20% . Journey Medical ( DERM ) +20% . Ventyx Biosciences ( VTYX ) +16% . PainReform ( PRFX ) +12% . iCAD ( ICAD ) +7% . Losers: Protagonist Therapeutics ( PTG...

2023-07-03 08:22:42 ET Baudax Bio ( BXRX ) -13% . VBI Vaccines ( VBIV ) -12% . Addentax Group ( ATXG ) -10% . AstraZeneca PLC ( AZN ) -7% . TOP Financial Group Limited ( TOP ) -4% . For further details see: AZN and VBIV amo...

2023-07-02 08:29:00 ET 3 Top Facts to Consider When Investing in Penny Stocks The allure of penny stocks, typically defined as stocks trading for less than $5 per share, has drawn countless investors to try their hand at uncovering the next big success story. They offer a tempting propo...

PreHevbri ® is the only approved 3-antigen hepatitis B vaccine for adults in the U.K. Product to be launched via marketing and distribution partner, Valneva VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful p...

2023-06-07 13:57:29 ET VBI Vaccines ( NASDAQ: VBIV ) added ~9% on Wednesday, albeit on below-average volumes, after the biotech announced an upcoming presentation on its Hepatitis B vaccine PreHevbrio at a European medical event later this month. The Cambridge, Massachusetts...

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that an abstract highlighting T-cell responses and durability of immune responses following vaccination with VBI’s 3-anti...